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ORIGINAL ARTICLE
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ABSTRACT
The 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme of the mevalonate pathway for the synthesis
of cholesterol in mammals (ergosterol in fungi), is inhibited by statins, a class of cholesterol lowering
drugs. Indeed, statins are in a wide medical use, yet statins treatment could induce side effects as hepato-
toxicity and myopathy in patients. We used Saccharomyces cerevisiae as a model to investigate the effects
of statins on mitochondria. We demonstrate that statins are active in S.cerevisiae by lowering the ergos-
terol content in cells and interfering with the attachment of mitochondrial DNA to the inner mitochondrial
membrane. Experiments on murine myoblasts confirmed these results in mammals. We propose that the
instability of mitochondrial DNA is an early indirect target of statins.
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1. Introduction
Cholesterol is a vital component of cell membranes, essential for
the synthesis of steroid hormones, bile acids, and vitamin D, but
high cholesterol levels are associated with an elevated risk of
cardiovascular diseases. Cholesterol (ergosterol in yeast) is the
end-product of the mevalonate pathway1. The enzyme 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase is the rate-
limiting step in the synthesis of cholesterol and it catalyses the
conversion of HMG-CoA to mevalonate; the mevalonate pathway
and the HMG-CoA enzyme, as well as its regulation are conserved
from yeast to humans2,3. HMG-CoA is the target of statins4, the
most prescribed drug class for lowering elevated LDL-cholesterol,
generally effective and well tolerated; however, patients can
experience muscle adverse effects such as myopathy5,6. Genetic
factors7 and drug-drug interactions8 also contribute as risk factors
for the development of muscle side effects in patients9,10.
Mitochondrial dysfunction has been described as responsible
for several statins side effects and serious adverse reactions; in
particular, various mitochondrial phenotypes were described such
as the decrease of respiratory chain function, alteration of calcium
homeostasis, ROS production, alteration of mitochondrial volume,
however, the primary effect of statins remains to be eluci-
dated11,12. The activity of statins was investigated previously in
the yeast Candida glabrata13 and in Saccharomyces cerevisiae14;
the yeast S. cerevisiae is an excellent unicellular model to gain
insights into human diseases15 in particular, those resulting from
impaired mitochondrial function16–18, because S. cerevisiae is able,
utilising fermentable carbon sources to survive without mitochon-
drial respiration. We previously demonstrated that ketoconazole,
which blocks the ergosterol biosynthetic pathway downstream the
HMG-CoA reductase, reduced the ergosterol content in yeast cells
and induced the loss of mitochondrial DNA; this phenomenon is
coupled with a re-localisation of Erg27 enzyme from Lipid
Droplets (LDs) to Endoplasmic Reticulum (ER)19. Here, we expand
the analysis of mitochondrial function and the stability of mito-
chondrial DNA using statins in S. cerevisiae: we showed that these
molecules cause a reduction of ergosterol, inducing loss of mito-
chondrial DNA and resulting in a reduction of mitochondrial res-
piration/function coupled with the Erg27 re-localisation in ER. In
murine myoblasts, upon statins treatment, we also observed a
reduction of mitochondrial DNA copy number associated with an
impaired differentiation capacity.
2. Materials and methods
2.1. Yeast strains and growth conditions
The strains used in this study: the S. cerevisiae W303 (MAT a,
his3–11, ade2–1, leu2–3, 112, ura3–1, trp1–1, can1–100), W303-
ERG27-GFP, MValC25T (MATa, ade2–1, ura3–52, leu2, kar1–1, syn);
the K. lactis PM6-7A (MATa uraA1-1 adeT-600a), PM6-7A/Dpda1
(Klpda1::Tn5BLE). The plasmid pVT100U-mitoGFP was used to visu-
alise mitochondria.
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Yeast culture media: YPD (1% bacto peptone, 1% yeast extract
and 2% glucose), was used as rich medium. YPG (1% bacto pep-
tone, 1% yeast extract and 3% glycerol), was the medium used to
verify the respiratory competence of yeast colonies. All media
were supplemented with 2.3% bacto agar (Difco) for solid media.
YPD medium supplemented with 0.5mg/ml of ergosterol.
Ergosterol and Tween 80 were dissolved in pure ethanol to final
concentration of 10mg/ml for ergosterol and 42% for Tween80,
and steamed at 100 C for 10min, always protected from light,
before being added to the medium. Yeast cultures were grown
and analysed in exponential phase at 28 C, unless other-
wise specified.
2.2. C2C12 cell culture
C2C12 myoblasts were grown at 5% CO2 and 37 ˚C in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) supplemented with 1%
penicillin/streptomycin (Gibco) and 10% foetal bovine serum
(Gibco). To induce differentiation, cells were cultured with
Dulbecco’s modified Eagle’s medium and 2% horse serum (Gibco)
for 48 h, when more than 90% of the cells had fused into myo-
tubes. C2C12 were treated for 48 with 25uM Atorvastatin in
growth medium and then induced to differentiate for further 48 h
either in the presence or absence (ctrl) of the compound.
2.3. Rho production
Strains (W303) devoid of mitochondrial DNA were produced as fol-
lows: cells were grown at the density of 1 106cells/ml on YPD
medium, phosphate buffer pH 6.5 was added in1ml of culture, at
the final concentration of 0.05M, and ethidium bromide at final
concentration of 50 lg/ml. The cultures were incubated at 28 C
for 24 h. Cells were washed twice, plated on YPD and incubated
at 28 C. The absence of mitochondrial DNA was assessed by DAPI
staining and absence of growth on glycerol containing medium as
a carbon source.
2.4. S. cerevisiae cell culture
The cells were pre-activated in YPD and YPD rich medium supple-
mented with different statin up to the stationary phase.
Subsequently, the cultures were all diluted to a concentration of
104 cells/ml with the respective media and incubated at 28 C.
The growth trend was monitored with the measurement of the
optical density OD600 and/or with the cell count with the
B€urker chamber.
2.5. Petites assay
Cells were grown in YPD until the stationary phase. At the con-
centration of 1 107cells/ml and 1 108cells/ml, 100 cells were
spotted in YPD plates and incubated at 28 C. After two days, col-
onies were replicated on YPG plates. The lack of rho cell growth
was assessed on glycerol as the carbon source and the absence of
mtDNA by 40,6-diamidino-2-phenylindole (DAPI; Sigma) staining.
2.6. Microscopy
Cells were observed with a Zeiss Axio Imager Z1 Fluorescence
Microscope with AxioVision 4.8 Digital Image Processing System,
the objective lens used was 63 Oil. Filter sets: 38HE (GFP), 43HE
(DsRed). Filters for GFP (470/40 nm excitation and 525/50 nm
emission) and DAPI (365-nm excitation and 445/450-nm emission),
were used Metamorph software (Universal Imaging, West Chester,
PA) was used to deconvolute Z-series and treat the images20.
2.7. Cells treatment
Pravastatin and simvastatin were hydrolysed in ethanolic NaOH
[15% (v/v) ethanol and 0.25% (w/v) NaOH] at 60 C for 1 h.
Atorvastatin and rosuvastatin were dissolved in H2Odd supple-
mented with 1% DMSO and 0.9% NaCl. Q10 was hydrolysed in
100% acetone.
Cells were grown to a density of 1 107cells/ml in YPD rich
medium supplemented with: pravastatin 150 mg/ml, atorvastatin
100 mg/ml, rosuvastatin 50mg/ml and Q10 10, 50mg/ml. The cells
treated were used for several assays.
2.8. Mass spectrometric analyses
Dry cell pellets were deep frozen by immersion in liquid nitrogen
and quickly ground to a powder using an IKA A11 basic laboratory
mill (IKA, Staufen, Germany). 300mg of cell pellet were transferred
to glass vials with 10ml Folch solvent (chloroform/methanol 2:1,
v/v) containing 0.01% butylated hydroxytoluene followed by the
addition of10ll of internal standard (19-hydroxy-cholesterol, 2mg/
ml in methanol) as internal standards (IS). The homogenisation
and extraction (60min) were carried out at room temperature
(RT). The extracts were evaporated under a stream of N2then the
dry residue was dissolved in1ml hydrolysis solution containing 5%
KOH in (MeOH/H2O, 95:5) and subjected to saponification (1 h,
80 C). The hydrolysed solution was extracted with 0.5ml distilled
H2O and 4ml diethyl ether. The ether phase was dried under a
stream of N2at RT. The samples were then reconstituted with
25 ll ethylacetate and vortex mixed. The fractions to be analysed
were converted to their trimethyl-silylated derivatives by heating
with 40ll BSTFA containing 1% TMCS at 70 C for 45min. The
sample was dried under a stream of N2. The residue was dissolved
in200ml hexane and the clear hexane phase was transferred into
a glass vial for GC–MS injection. GC–MS analyses were performed
with an Agilent 6850 A gas chromatograph coupled to a 5973N
quadrupole mass selective detector (Agilent Technologies, Palo
Alto, CA, USA).
Chromatographic separations were carried out with an Agilent
HP5msfused-silica capillary column (30m 0.25mm i.d.) coated
with 5%-phenyl-95%-dimethylpolysiloxane (film thickness 0.25 lm)
as stationary phase. Injection mode: splitless at a temperature of
280 C. Column temperature programme: 120 C (1min) then to
320 C at a rate of 5 C/min and held for 5min. The carrier gas
was helium at a constant flow of 1.0ml/min. The spectra were
obtained in the electron impact mode at 70 eV ionisation energy;
ion source 280 C; ion source vacuum10-5 Torr. MS analysis was
performed simultaneously in TIC (mass range scan from m/z50 to
800 at a rate of 0.42 scans s-1) and SIM mode. For GC-SIM-MS
analysis, ion m/z 363 was selected for ergosterol and ion m/z 353
was selected for the internal standard.
2.9. O2 consumption measurement
Respiration studies were performed using a Clark oxygen elec-
trode (Hansatech Instruments) as described in De Luca et al.
(2009)21. Cells (1 108) were collected, washed with 1ml sterile
water, suspended in 1ml sodium phosphate buffer (10mM pH 7.4
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containing 4 g l1 glucose) and loaded in the reaction vessel of
the previously calibrated oxygen electrod22.
2.10. Immunofluorescence
For the immunofluorescence on C2C12 cells were fixed with 4%
paraformaldehyde in PBS for 20min at RT, and permeabilized with
0.5% Triton X-100 in PBS. After 1 h incubation with blocking solu-
tion (4% BSA in PBS), primary antibody for MyHC (DSHB, clone
MF20; 1:50 in blocking solution) was incubated overnight (O/N) at
4 C. A goat anti-mouse secondary antibody coupled to Alexa
Fluor 488 (Thermo Fisher; A21202; 1:250 in blocking solution) was
then incubate for 1 h. DNA was counterstained with DAPI (Sigma;
D9542). Coverslips were mounted in ProLongTM Diamond
Antifade Mountant (Invitrogen; p36970). ImageJ was used to
quantify the percentage of nuclei inside the myotubes compared
to control (Differentiation index). Images were taken with Nikon
eclipse TE300 microscope. Pictures showed in the figures are rep-
resentative of all examined fields.
2.11. Quantitative analysis of mitochondrial DNA
Total DNA was isolated using phenol/chloroform-extraction.
mtDNA was quantified by q-PCR using PowerUpSYBR Green PCR
Master mix (Applied Biosystems; 4367659) and analysed on a
StepOne Plus Real-Time PCR System (Applied Biosystems). To
evaluate the amount of mtDNA present per nuclear genome, we
quantified the relative copy number differences through the DDCt
method23, comparing mtDNA and nuclear DNA using the
following primers sequences: mtDNA CYTOCHROME C (mt-CO1)
FW: 50-TCATCCCTTGACATCGTGCT-3’ RV: 50-GTCTGAGTAGCGT
CGTGGTA-3’; nuclear DNA ACTIN BETA (ACTB) FW: 50-
CCCTGAGTGTTTCTTGTGGC-30 RV: 50-GTCTCCGGAGTCCATCACAA-30.
3. Results
3.1. Statins induced a petite phenotype in S. cerevisiae
As a potent HMG-CoA inhibitor, statins reduce cellular ergosterol
levels also in S. cerevisiae. Indeed, the effect of lovastatin on yeast
was previously investigated in the S. cerevisiae wild type
2180–1A14,24 and BY4741 (derivative of S288C) model laboratory
strains25. Similarly, the effect of the additional statins, including
rosuvastatin, atorvastatin, simvastatin and fluvastatin was tested in
the BY4742 genotype, expressing the human orthologue of
HMG-CoA26.
Herein, we used S. cerevisiae W303 yeast cells to investigate
the effects of human HMG-CoA reductase inhibitors; W303 is an
excellent model to study sterols because the level of sterols is
higher than in S288C and derivative strains27,28.
Figure 1. Statins induced a high percentage of petites production in yeast cells. (a) Percentage of petites production of wild type W303 and W303 rho grown in YPD
medium and wild type W303 grown in YPD medium with pravastatin 150 mg/ml, atorvastatin 100 mg/ml and rosuvastatin 50 mg/ml. (b) The petite phenotype is sup-
pressed by ergosterol. The same statins treatments as in (a) didn’t show a petite phenotype production in cells grown in a medium supplemented with ergosterol (0,5
mg/ml, YPDE). Cultures grown 24, 48 and 72 hours were plated on YPD plates and petites were counted after a replica plating on glycerol containing medium. Data
are the average of 3 independent experiments and standard deviation is indicated. The asterisks indicate significant modulations (p < 0.05) according to Student’s
T-test.
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To assess the effect of statins on mitochondria, we selected
pravastatin, rosuvastatin, and atorvastatin for our studies, at non-
toxic concentrations (Supplementary Figure 1) previously used to
study the effect of statins on yeast26. The treatment of wild type
W303 cells with statins on agar YPD, led to the production of
high percentage of small colonies. These colonies are referred to
as petites, a phenotype which indicates a mitochondrial dysfunc-
tion, hence we assessed the effects of statins on yeast mitochon-
drial function using a petite assay (Supplementary Figure 2). The
petite phenotype refers to the size of a S. cerevisiae colony with
rearrangements (rho) or the lack of mitochondrial DNA (rho).
We monitored petite production plating the cultures at 24, 48,
72 h of growth. At the concentration used, the statins induced a
high rate of petite phenotype, especially atorvastatin and rosuvas-
tatin (Figure 1(A)), demonstrating that the statins induced a defect
in mitochondrial function, similar to ketoconazole.
We previously show that in yeast, the presence of ergosterol
(0.5mg/ml) in growth medium suppressed the petite phenotype
induced by ketoconazole19. We verified if the generation of petite
colonies in presence of statins could be counteracted by adding
ergosterol, at a concentration used to suppress the ketoconazole
effects. Indeed, the percentage of petite was very low in presence
of ergosterol, in similar to the wild type strain with functional
mitochondria (Figure 1(B)).
Because treated cells showed different size, we verified cellular
vitality by counting cells number to construct growth curves,
which is not consider with optical density measure
(Supplementary Figure 3(A)). Of note, treatments of W303 with
statins resulted in intermediate growth curves, located between
the non-treated W303 strain and the strain devoid of mitochon-
drial DNA (W303 rho), while the presence of ergosterol in the
medium restores a wild type growth in statin treated cells and in
W303 rho (Supplementary Figure 3(B)). These results suggest that
statins treatment induced mitochondrial dysfunction in S. cerevi-
siae by lowering ergosterol content. To verify this hypothesis, we
measured the content of ergosterol in W303 wild type cells
treated with statins, using, as a control, W303 rho strain, which
has a low ergosterol content17. Ergosterol content was measured
in yeast cells treated with statins by gas chromatography-mass
spectrometry (GC-MS) (Figure S4). The results revealed that ergos-
terol content was significantly lower in statin-treated cells, com-
pared with the non-treated wild type strain. These results are in
agreement with a previous study in Candida glabrata, demon-
strates that simvastatin reduces ergosterol quantities in cells17.
3.2. The petite colonies induced by statin treatment contain
rho cells, devoid of mitochondrial DNA
To establish if statins act directly on the stability of mitochondrial
DNA, because of low ergosterol content, we visualised mitochon-
drial DNA from petite colonies by DAPI staining. Results, reported
in Figure 2(A), showed that wild type cells contained mitochon-
drial DNA, W303 rho cells had only nuclear DNA and wild type
cells treated with statins showed a high percentage of cells
devoid of mitochondrial DNA. The quantitative analysis of rho
Figure 2. Statins treatments induced the loss of mitochondrial DNA and the ergosterol suppressed this phenotype. (a) DAPI staining of cells presented in Fig. 1; wild
type W303, W303 rho and wild type W303 treated with pravastatin 150 mg/ml, atorvastatin 100 mg/ml and rosuvastatin 50 mg/ml grown in YPD and YPDE media
(YPD supplemented with 0,5mg/ml ergosterol). Bar: 2 mm. The magnification is the same in each picture. (b) The histogram shows the percentage of cells without
mitochondrial DNA. An average of 300 cells were counted.
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cells generated by statins is reported in Figure 2(B): histograms
report the percentage of cells without mitochondrial DNA. The
same experiment was performed in parallel with cultures grown
in YPDE medium.
Results demonstrated that statins induced the loss of mito-
chondrial DNA and that the presence of ergosterol suppressed
this phenotype; we also verified that the colonies with mitochon-
drial DNA were able to grow on glycerol medium (not shown).
This result indicate that loss of mitochondrial DNA was correlated
to low concentration of ergosterol in the mitochondrial mem-
branes and that the exogenous addition of ergosterol was suffi-
cient to stabilise the mitochondrial DNA, counteracting the statins
effect. We then measured the oxygen consumption of cells
treated with statins; Figure 3(A) reports that the respiration rate of
wild type strain treated with statins is lower if compared with the
non-treated wild type cells; when the same cultures were grown
in YPD medium supplemented with ergosterol, the respiration
rate was higher, indicating that the presence of ergosterol com-
pensate for the effect of statins (Figure 3(B)). This result suggests
an impairment of the respiratory chain function when cells were
treated with statins (see Discussion).
3.3. Statins treatment resulted in mitochondrial
morphology defects
In yeast, cells lacking mitochondrial DNA or a conditional mutant
(ERG27) of the ergosterol pathway show defects in mitochondrial
morphology19 and a down regulation of the ergosterol genes
results in mitochondrial membrane alteration29,30. We therefore
analysed mitochondrial morphology after statins treatment (Figure
4(A)). Accordingly, wild type strain transformed with a vector
expressing the mitoGFP for green fluorescent labelling of mito-
chondria in living cells, and mitochondrial morphology was
assessed upon treatment with statins at exponential phase, in glu-
cose-containing medium with or without ergosterol. By fluores-
cence microscopy, we observed a relevant percentage of
aggregated vs tubular mitochondria in wild type strain treated
with statins. This phenotype is reminiscent of mutants lacking
mitochondrial DNA, or of W303 rho strain19. The addition of
ergosterol partially suppressed the aggregated mitochondrial
morphology phenotype, partially restoring a tubular mitochondrial
structure (Figure 4(B)). By staining cells with DAPI, we were able
to verify the presence of mitochondrial DNA in the strains express-
ing mitoGFP, treated with statins, and supplemented with ergos-
terol (Supplementary Figure 5).
3.4. Statins induced a cellular re-localisation of Erg27, a sensor
of mitochondrial dysfunction
Erg27 is an essential enzyme of the ergosterol biosynthetic pathway
that plays as a sensor of mitochondrial function: in wild type cells
the enzyme is mainly found in Lipid Droplets (LDs), while in cells
with a block of respiration or in rho cells, it moves to the nuclear
and cortical Endoplasmic Reticulum (ER)19. To assess a possible
mitochondrial defect, we determined the cellular localisation of
Erg27 following statins treatment. Wild type W303 and W303 rho
strains, harbouring the ERG27-GFP fusion integrated in the genome,
were treated with statins and analysed by fluorescence microscopy.
Results reported in Figure 5 showed that in wild type cells, Erg27-
GFP decorated lipid droplets, while in cells treated with statins,
Erg27-GFP re-localised in nuclear and cortical ER, as in W303 rho
cells. The re-localisation of Erg27-GFP demonstrated that statins,
similarly to a block of respiration, induced the movement of Erg27
from lipid droplets to the endoplasmic reticulum.
3.5. Effect of statins on the respiratory obligate yeast
Kluyveromyces lactis
The yeast Kluyveromyces lactis has a metabolism similar to that of
human cells and the regulation between fermentative and respira-
tory metabolism depends on oxygen availability; moreover, in
K. lactis, as in human cells, cells cannot survive without mitochon-
drial DNA31. We analysed the effect of statins on K. lactis growth,
in order to enlighten the effects of statins on respiration in a yeast
that could mimic the human cell behaviour. The K. lactis Dpda1, a
mutant strain lacking the pyruvate dehydrogenase E1a subunit19,
was used to mimic the growth behaviour of a S. cerevisiae rho
strain. Statins treatments resulted in a slight delay in growth,
intermediate between the untreated wild type and the Dpda1
mutant strain with a defective respiration (Supplementary
Figure 6). This experiment demonstrated that statins are effective
Figure 3. The oxygen consumption rate of yeast cells treated with statins is low
compared to the wild type strain. (a) Oxygen consumption of W303, W303 rho
and W303 cells treated with statins in YPD medium showed low oxygen con-
sumption in cells treated with statins; (b) The respiration rate is higher when the
same cultures were grown in YPD medium supplemented with ergosterol. The
oxygen consumption rate is expressed as O2 nmol/ml, and the respiration rates
was normalized for cell number.
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also in a yeast unable to lose spontaneously mitochondrial DNA,
as for human cells.
3.6. Effect of statins in a yeast model of human MELAS
mitochondrial disease
Statins are not recommended for patients affected by mitochon-
drial diseases32 and patients with Mitochondrial
Encephalomyopathy, Lactic Acidosis and Stroke-like episodes
(MELAS) experienced myotoxicity33,34. A yeast model for MELAS
mitochondrial disease exists: the strain C25T containing the C25T
mutation in the mitochondrial tRNALeu (UUR), is the yeast coun-
terpart of the human mitochondrial C3256T mutation in the
tRNALeu (UUR) gene, identified in MELAS patients35. The C25T
mitochondrial mutation induces a reduced growth on a respira-
tory carbon source and shows mitochondrial morphology
defects36. In order to verify if the effect of statins treatment could
be additive on the yeast MELAS phenotypes, we followed the
growth of C25T cells with statins (Supplementary Figure 7). The
treatment with statins causes a mild effect on growth in exponen-
tial phase, intermediate between rho cells and the non-treated
mutant. Of note, pravastatin seems to exert a greater effect,
inducing a lag phase in growth. This experiment showed that sta-
tins exacerbated the mitochondrial dysfunction of a yeast strain
with impaired mitochondrial function.
3.7. In vitro effects of statins on C2C12 murine cells
In light of the evidence that statins assumption is often associated
with muscle-related side effects, such as fatigue, muscle pain and
muscle weakness, we sought to verify the effect of statins on a
well-established in vitro model of myogenesis, the C2C12 murine
myoblasts cell line37. To this end, we assessed the differentiation
capacity of C2C12 upon atorvastatin (25 mM) treatment, as com-
pared to untreated cells (Ctrl) by immunofluorescence for Myosin
heavy chain, a marker of terminal myogenic differentiation. As
shown in Figure 6, atorvastatin dramatically reduced C2C12 myo-
genic differentiation (Figure 6(A)), as quantified evaluating differ-
entiation index (Figure 6(B)). To verify if the observed
differentiation defects were also accompanied with mitochondrial
dysfunction, we measured the mitochondrial DNA content by qRT-
PCR (see Methods). The threshold of amplification between
mtDNA (mt-CO1 gene) and nuclear DNA (using ACTB as reference)
was measured; the average of ratio of treated/non-treated was
0.96 ± 0.015 (mean± standard deviation) (mean of n¼ 4 replicates),
indicated that atorvastatin induced a dose-dependent reduction
of mitochondrial DNA, in agreement with data obtained in
yeast cells.
4. Discussion
Statin intolerance is often a consequence of statin-associated
myopathy38,39; hence, it is fundamental to understand the molecu-
lar effect of statin in the cells. Yeast is recognised as a good
Figure 4. Statins treatments in S. cerevisiae results in an aberrant mitochondrial morphology phenotype, similar to that of rho cells and this phenotype is suppressed
by ergosterol. (a) W303 was treated with pravastatin 150 mg/ml, atorvastatin 100mg/ml and rosuvastatin 50 mg/ml grown in YPD and YPDE media in exponential
growth phase; mitochondria were visualized with mitoGFP. (b) The histogram shows the percentage of cells with tubular mitochondria. As a control, W303 rho strain
was used. Bar: 2 mm. The magnification is the same in each picture.
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model to study the cellular mechanisms of mitochondrial human
diseases and S. cerevisiae is unique among yeasts because it is
able to survive with non-functional mitochondria17. We confirmed
here that statins act as cholesterol lowering drugs in S. cerevisiae
as was previously published14; mass spectrometry analysis
revealed a lower ergosterol content in statins treated cells than
the wild type strain (Supplementary Figure 1); in yeast cells
treated with statins, the Erg27 enzyme localised in the endoplas-
mic reticulum indicating low level of ergosterol, because in cells
with normal ergosterol content, the enzyme is localised in lipid
droplets19 (Figure 5). Of note, statin treatments resulted in W303
growth curves rates intermediate between the non-treated strain
(W303) and the strain devoid of mitochondrial DNA (W303 rho),
while the supply of ergosterol in the medium restores a wild type
growth in statin treated cells and in W303 rho (Supplementary
Figure 3(B)). Also, the growth curves of the yeast K. lactis, which
has a metabolism more similar to human cells, revealed that sta-
tins slightly impair the growth, as in S. cerevisiae (Supplementary
Figure 6). Finally, we treated with statins a yeast model of human
MELAS disease18. Statins are not administered to MELAS patients
because they precipitate myopathic symptoms40; indeed, we
found an effect on C25T strain growth, indicating an additive
negative affect of stations if associated with a MELAS mutation
(Supplementary Figure 7).
Taking together these results indicate that S. cerevisiae is a suit-
able model to investigate the mitochondrial effects of statins and
also to enlighten the regulation of ergosterol pathway based on
the dynamic localisation of Erg enzymes in the cell. Another case
of relocalization of an enzyme of the ergosterol biosynthetic path-
way was previously described: Erg1 shows a dual localisation both
in the ER and LDs, but it is redistributed from LDs to ER in low
iron condition in the cells41. The cross talk between the mitochon-
drial respiration and the ergosterol biosynthetic pathway is still
poorly understood19.
Statins induce a petite phenotype (Figure 1(A) and Supplementary
Figure 2), caused by the loss of mitochondrial DNA (Figure 2A); S.
cerevisiae is able to survive without mitochondrial DNA (rho cells)
but can also maintain rearrangements of mitochondrial DNA (rho
cells), induced by chemical agents or by genetic mutations42. The
lack of mitochondrial DNA in statin treated cells, suggested an effect
of statins in the stability of mitochondrial DNA and not in mitochon-
drial DNA transcription/replication/recombination. The percentage of
treated cells showing cells devoid of mitochondrial DNA (Figure 2(B))
fits well with the percentage of petite colonies (Figure 1(A)).
The supplementation of ergosterol in the growth medium was
able to suppress the mitochondrial DNA loss (Figures 1(B) and
2(A)), demonstrating that a correct amount of ergosterol is essen-
tial for mitochondrial function.
To date, a demonstration of how mitochondrial DNA molecules
are attached to the inner mitochondrial membrane is still lacking,
but lipid rafts, membrane microdomains enriched in cholesterol
and sphingolipids43 are essential to maintain mitochondrial DNA
in human cells44. Furthermore, the maintenance of mitochondrial
nucleoids is coordinated with the mitochondrial fusion and fission
machinery to ensure the distribution of mitochondrial DNA in the
cells45; of note, the mitochondrial protein ATAD3, which binds
cholesterol in the inner mitochondrial membrane, has been pro-
posed to have a central role in nucleoid organisation46–49.
The statins investigated in this work showed different behav-
iours: pravastatin produced less petites, it is less toxic, but the
ergosterol content is comparable to other statins, and the respir-
ation is more similar to the wild type strain. Rosuvastatin pro-
duced the higher percentage of petites and it is more toxic, and
the respiration is similar to rho cells. Atorvastatin is intermediate
between pravastatin and rosuvastatin. The same behaviour is
observed when K. lactis was treated with the statins.
An extensive literature reports defects in respiration in mam-
malian cells treated with statins, by measuring the activity of
respiratory chain complexes50. We hypothesise that the mitochon-
drial defects described in literature can be reconciled/explained
by the low levels of mitochondrial DNA copy number, that imbal-
ance the ratio between mitochondrial and nuclear-encoded subu-
nits of the respiratory complexes, resulting in an altered
respiration rate. Indeed, yeast cells treated with statins showed a
respiration rate lower than the wild type strain but, when the
same cultures were grown in YPD medium were supplemented
Figure 5. Statins treatments induced the re-localization of Erg27, a sensor of
mitochondrial state, from lipid droplets to nuclear and cortical ER. The Erg27
localization in wild type cells is predominantly in lipid droplets, while in rho cells
the enzyme is mainly in nuclear and cortical endoplasmic reticulum. Wild type
W303 with the ERG27-GFP fusion integrated in the genome was visualized at
fluorescence microscopy after statins treatments, pravastatin 150mg/ml, atorvasta-
tin 100mg/ml and rosuvastatin 50mg/ml in exponential growth phase in YPD
medium. Bar: 2 mm. The magnification is the same in each picture.
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with ergosterol, the respiration rate was higher (Figure 3). Of note,
the complex II is the only to be entirely nuclear encoded (i.e. this
complex does not contain mitochondrial encoded subunits);
indeed, the complex II resulted unaffected by simvastatin treat-
ment on skeletal muscle51,52; on the contrary, the other respiratory
complexes contain nuclear and mitochondrial- encoded subunits
are affected by statins42; we hypothesise that a reduced level of
mitochondrial DNA could results in an imbalance of the nuclear
and mitochondrial encoded subunits, causing an altered respir-
ation rate.
Of note, skeletal muscle biopsies from patients diagnosed with
myopathies induced by statins, were used to quantify mitochon-
drial DNA relative to nuclear DNA (mitochondrial DNA content) by
qPCR, and it was found that skeletal muscle mitochondrial DNA is
decreased in patients with statin-induced myopathy53,54. In agree-
ment with this, we observed a small but significant reduction of
mitochondrial DNA in C2C12 myoblasts after statin treatment. This
reduction could explain why muscle cells are more sensitive to
statins than other cells, resulting in muscle-related side effects.
Indeed, mitophagy has been reported to be essential for proper
muscle differentiation55 and during muscle differentiation, 4 times
more DNA and 8 times more respiratory complexes are needed
compared to other cells56. Our results support the notion that the
amount of mitochondrial DNA is critical in muscle differentiation
because after degradation of mitochondria, new mitochondrial
DNA synthesis and new membranes are needed to maintain func-
tional myofibers. The statins-induced reduction of the amount of
cholesterol necessary to maintain mitochondrial DNA, and for
membrane construction, might be the reason why chronic statins
treatment induces muscle-related side effects. Accordingly, in
presence of statins the differentiation from myoblast to myotubes
is dramatically reduced (Figure 6).
In conclusion, we have used S. cerevisiae as a model to study
the mechanism of statin side effects on mitochondria, and we
confirm that a relevant effect of low cholesterol level induced by
statins is on mitochondrial DNA stability, explaining why muscle
cells are more prone to statins side effects.
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